Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Get today's Klotho Neuroscience stock news. We cover the latest Klotho Neuroscience headlines and breaking news impacting Klotho Neuroscience stock performance.

Review the current Klotho Neurosciences Inc (KLTO:XNAS) dividend yield and history to decide if KLTO is the best investment for you.

A high-level overview of Klotho Neurosciences, Inc. WT EXP 062129 (KLTOW) stock. View (KLTOW) real-time stock price, chart, news, analysis, analyst reviews and more.

See Klotho Neurosciences, Inc. (KLTO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.